TP53 and sarcoma: These trends were consistent in both trial subgroup analysis, except for neoadjuvant polychemotherapy in the ProfiLER cohort, which displayed an ORR of 67% (n = 5/15) and 66% (n = 3/5) in TP53 WT and mutated sarcomas, respectively.